Proteome-Based Subtyping of Multisystem Disease: A Comprehensive Review for Clinicians

Abstract

Proteome-based subtyping represents a transformative approach in the management of multisystem diseases, characterized by the integration of high-throughput proteomic data to delineate clinically meaningful subgroups. By leveraging advances in mass spectrometry, bioinformatics, and systems biology, clinicians and researchers are now able to achieve unprecedented resolution in disease classification beyond conventional clinical and genetic criteria. This review synthesizes current evidence on proteome-guided disease stratification, emphasizing its application in complex multisystem disorders, clinical utility, and implications for precision medicine.

Introduction

Multisystem diseases, such as systemic lupus erythematosus, sarcoidosis, and systemic vasculitides, pose unique clinical challenges due to their heterogeneity in presentation, progression, and response to therapy. Traditional subtyping methods based on clinical features or genomics frequently fail to capture the dynamic molecular landscape that drives disease variability. Proteomics—the large-scale study of proteins and their modifications—offers a functional readout of cellular processes and holds promise for refining disease subtypes. This article provides an in-depth analysis of proteome-based subtyping in multisystem diseases, with a focus on pathophysiological mechanisms, clinical ramifications, and future directions in disease management.

Epidemiology / Disease Burden

Multisystem diseases collectively affect millions worldwide and are a significant cause of morbidity and mortality, particularly in younger adults. Epidemiological studies indicate increasing incidence rates, partly due to improved diagnostic capabilities and heightened awareness. However, the variable disease course and unpredictable organ involvement contribute to substantial healthcare utilization and impaired quality of life. Accurate subtyping is essential to optimize resource allocation and improve patient outcomes, highlighting the urgent need for molecularly informed classification systems.

Pathophysiology

The pathogenesis of multisystem diseases involves complex interactions between genetic susceptibility, environmental triggers, and dysregulated immune responses. Proteomic profiling enables the identification of distinct molecular pathways operational in various disease subtypes. For example, in systemic lupus erythematosus, proteomic signatures have revealed subgroups driven by interferon signaling, complement activation, or neutrophil extracellular traps. This mechanistic insight allows for a more nuanced understanding of disease biology and facilitates the identification of novel therapeutic targets.

Risk Factors

Risk factors for multisystem diseases are multifactorial and include both inherent (genetic) and acquired (environmental, infectious, lifestyle) components. Proteome-based subtyping has elucidated previously unrecognized risk clusters, such as specific autoantibody profiles, post-translational protein modifications, and inflammatory mediators that predispose certain individuals to severe or refractory disease. These findings are instrumental in guiding early intervention strategies and individualizing risk assessment.

Clinical Features

Multisystem diseases manifest with a wide spectrum of clinical features, often involving multiple organ systems such as the skin, joints, kidneys, lungs, and nervous system. Proteomic approaches have enabled the correlation of specific protein expression patterns with clinical phenotypes, such as renal involvement, cutaneous manifestations, or neuropsychiatric symptoms. These correlations facilitate the development of predictive models that aid clinicians in anticipating disease trajectory and tailoring monitoring protocols accordingly.

Diagnosis

Traditional diagnostic criteria for multisystem diseases rely on clinical findings, laboratory markers, and, increasingly, genetic information. Proteome-based subtyping adds another dimension by providing functional biomarkers that enhance diagnostic precision. Mass spectrometry-based assays and targeted proteomic panels are now being integrated into diagnostic algorithms, enabling earlier detection of disease flares, stratification of disease severity, and identification of atypical presentations. This proteomic data, when combined with clinical and genetic information, supports a multi-omics approach to personalized diagnosis.

Treatment & Management

Management of multisystem diseases is often challenging due to heterogeneous treatment responses and the risk of adverse effects from immunosuppressive therapies. Proteome-based subtyping facilitates the selection of targeted therapies by identifying patient subgroups most likely to benefit from specific interventions. For instance, patients with proteomic signatures indicating complement activation may respond favorably to complement inhibitors, while those driven by type I interferon pathways may benefit from agents targeting interferon signaling. This stratified approach minimizes unnecessary exposure to ineffective treatments and optimizes therapeutic outcomes.

Recent Advances / Emerging Therapies

Recent advances in proteomics, including single-cell proteomics, phosphoproteomics, and spatial proteomics, have expanded the scope of disease subtyping. Emerging therapies informed by proteomic discoveries include monoclonal antibodies, small molecule inhibitors, and novel biologics tailored to specific molecular pathways. Additionally, machine learning and artificial intelligence are increasingly employed to integrate complex proteomic datasets, improve subtype classification, and predict treatment response. These innovations are rapidly translating into clinical trials and, ultimately, routine clinical practice.

Guideline Recommendations

International guidelines are beginning to incorporate proteomic insights into disease management algorithms. The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have acknowledged the potential of molecular subtyping for risk stratification and individualized therapy, recommending further research and validation in large patient cohorts. As proteomic technologies become more accessible, guideline committees are expected to formally endorse proteome-based subtyping for select multisystem diseases in the near future.

Conclusion

Proteome-based subtyping marks a pivotal shift in the understanding and management of multisystem diseases. By capturing the dynamic protein landscape underpinning disease heterogeneity, this approach enables more precise diagnosis, risk assessment, and treatment selection. Ongoing research, technological refinement, and integration into clinical practice are essential to fully realize the promise of proteomics in precision medicine. As evidence accumulates, proteome-guided subtyping is poised to become a cornerstone of personalized care for patients with complex multisystem disorders.